Protagonist Therapeutics Aktie
132,76
USD
+7,59
USD
+6,06
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Protagonist Therapeutics Aktie Analyse
| 08.07.19 | Protagonist Therapeutics Buy | H.C. Wainwright & Co. | |
| 22.02.19 | Protagonist Therapeutics Outperform | BMO Capital Markets | |
| 29.01.18 | Protagonist Therapeutics Buy | Stifel, Nicolaus & Co., Inc. | |
| 21.07.17 | Protagonist Therapeutics Buy | BTIG Research | |
| 06.09.16 | Protagonist Therapeutics overweight | Barclays Capital |
Werbung
Werbung